Clinical Utility of a Plasma-Based miRNA Signature Classifier Within Computed Tomography Lung Cancer Screening: A Correlative MILD Trial Study
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Purpose: Recent screening trial results indicate that low-dose computed tomography (LDCT) reduces lung cancer mortality in high-risk patients. However, high false-positive rates, costs, and potential harms highlight the need for complementary biomarkers. The diagnostic performance of a noninvasive plasma microRNA signature classifier (MSC) was retrospectively evaluated in samples prospectively collected from smokers within the randomized Multicenter Italian Lung Detection (MILD) trial. Patients and Methods: Plasma samples from 939 participants, including 69 patients with lung cancer and 870 disease-free individuals (n = 652, LDCT arm; n = 287, observation arm) were analyzed by using a quantitative reverse transcriptase polymerase chain reaction–based assay for MSC. Diagnostic performance of MSC was evaluated in a blinded validation study that used prespecified risk groups. Results: The diagnostic performance of MSC for lung cancer detection was 87% for sensitivity and 81% for specificity across both arms, and 88% and 80%, respectively, in the LDCT arm. For all patients, MSC had a negative predictive value of 99% and 99.86% for detection and death as a result of disease, respectively. LDCT had sensitivity of 79% and specificity of 81% with a false-positive rate of 19.4%. Diagnostic performance of MSC was confirmed by time dependency analysis. Combination of both MSC and LDCT resulted in a five-fold reduction of LDCT false-positive rate to 3.7%. MSC risk groups were significantly associated with survival (χ 1 2 = 49.53; P < .001). Conclusion: This large validation study indicates that MSC has predictive, diagnostic, and prognostic value and could reduce the false-positive rate of LDCT, thus improving the efficacy of lung cancer screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
Circulating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., Guo, J., Zhang, Y., Chen, J., Guo, X., et al. (2008) · Cell Research · doi:10.1038/cr.2008.282 · Cited by 4,560
Arroyo, J. D., Chevillet, J. R., Kroh, E. M., Ruf, I. K., Pritchard, C. C., Gibson, D. F., Mitchell, P. S., Bennett, C. F., Pogosova-Agadjanyan, E. L., Stirewalt, D. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019055108 · Cited by 3,294
Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & Pepe, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,854
Characterization of extracellular circulating microRNA
Turchinovich, A., Weiz, L., Langheinz, A., & Burwinkel, B. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr254 · Cited by 1,941
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review
Iorio, M. V., & Croce, C. M. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100209 · Cited by 1,739
Benefits and Harms of CT Screening for Lung Cancer: A Systematic Review
Bach, P. B., Mirkin, J. N., Oliver, T. K., Azzoli, C. G., Berry, D. A., Brawley, O. W., Byers, T., Colditz, G. A., Gould, M. K., Jett, J. R., et al. (2012) · JAMA · doi:10.1001/jama.2012.5521 · Cited by 1,244
The majority of microRNAs detectable in serum and saliva is concentrated in exosomes
Gallo, A., Tandon, M., Alevizos, I., & Illei, G. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030679 · Cited by 1,060
Cited by
Global Epidemiology of Lung Cancer
Barta, J. A., Powell, C. A., & Wisnivesky, J. P. (2019) · Annals of Global Health · doi:10.5334/aogh.2419 · Cited by 1,575
Current and future perspectives of liquid biopsies in genomics-driven oncology
Heitzer, E., Haque, I. S., Roberts, C. E. S., & Speicher, M. R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0071-5 · Cited by 1,557
Gridelli, C., Rossi, A., Carbone, D. P., Guarize, J., Karachaliou, N., Mok, T., Petrella, F., Spaggiari, L., & Rosell, R. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.9 · Cited by 1,083
Progress and prospects of early detection in lung cancer
Blandin Knight, S., Crosbie, P. A., Balata, H., Chudziak, J., Hussell, T., & Dive, C. (2017) · Open Biology · doi:10.1098/rsob.170070 · Cited by 935
Molecular profiling for precision cancer therapies
Malone, E. R., Oliva, M., Sabatini, P. J. B., Stockley, T. L., & Siu, L. L. (2020) · Genome Medicine · doi:10.1186/s13073-019-0703-1 · Cited by 913
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments
Lone, S. N., Nisar, S., Masoodi, T., Singh, M., Rizwan, A., Hashem, S., El-Rifai, W., Bedognetti, D., Batra, S. K., Haris, M., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01543-7 · Cited by 819
The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics
Cheng, T.-Y. D., Cramb, S. M., Baade, P. D., Youlden, D. R., Nwogu, C., & Reid, M. E. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.021 · Cited by 600
Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 568
Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges
Seijo, L. M., Peled, N., Ajona, D., Boeri, M., Field, J. K., Sozzi, G., Pio, R., Zulueta, J. J., Spira, A., Massion, P. P., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.023 · Cited by 539
Self-citationPastorino, U., Silva, M., Sestini, S., Sabia, F., Boeri, M., Cantarutti, A., Sverzellati, N., Sozzi, G., Corrao, G., & Marchianò, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz117 · Cited by 523
Self-citationMicroRNAome genome: A treasure for cancer diagnosis and therapy
Berindan‐Neagoe, I., Monroig, P. D. C., Pasculli, B., & Calin, G. A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21244 · Cited by 522
Adams, S. J., Stone, E., Baldwin, D. R., Vliegenthart, R., Lee, P., & Fintelmann, F. J. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01694-4 · Cited by 467
Clinical utility of circulating non-coding RNAs — an update
Anfossi, S., Babayan, A., Pantel, K., & Calin, G. A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0035-x · Cited by 450
Mazzone, P. J., Silvestri, G. A., Patel, S., Kanne, J. P., Kinsinger, L. S., Wiener, R. S., Soo Hoo, G., & Detterbeck, F. C. (2018) · Chest · doi:10.1016/j.chest.2018.01.016 · Cited by 348
Predicting Malignant Nodules from Screening CT Scans
Hawkins, S., Wang, H., Liu, Y., Garcia, A., Stringfield, O., Krewer, H., Li, Q., Cherezov, D., Gatenby, R. A., Balagurunathan, Y., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.07.002 · Cited by 293
The Roles of MicroRNA in Lung Cancer
Wu, K.-L., Tsai, Y.-M., Lien, C.-T., Kuo, P.-L., & Hung, J.-Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071611 · Cited by 284
miR-Test: A Blood Test for Lung Cancer Early Detection
Montani, F., Marzi, M. J., Dezi, F., Dama, E., Carletti, R. M., Bonizzi, G., Bertolotti, R., Bellomi, M., Rampinelli, C., Maisonneuve, P., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv063 · Cited by 278
Challenges in Using Circulating miRNAs as Cancer Biomarkers
Tiberio, P., Callari, M., Angeloni, V., Daidone, M. G., & Appierto, V. (2015) · BioMed Research International · doi:10.1155/2015/731479 · Cited by 271
Biomarker Discovery and Validation: Statistical Considerations
Ou, F.-S., Michiels, S., Shyr, Y., Adjei, A. A., & Oberg, A. L. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.1616 · Cited by 258
Mazzone, P. J., Silvestri, G. A., Souter, L. H., Caverly, T. J., Kanne, J. P., Katki, H. A., Wiener, R. S., & Detterbeck, F. C. (2021) · Chest · doi:10.1016/j.chest.2021.06.063 · Cited by 254
Ebrahimi, H., Aryan, Z., Saeedi Moghaddam, S., Bisignano, C., Rezaei, S., Pishgar, F., Force, L. M., Abolhassani, H., Abu-Gharbieh, E., Advani, S. M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00164-8 · Cited by 237
Self-citationThe Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring
Batool, S. M., Yekula, A., Khanna, P., Hsia, T., Gamblin, A. S., Ekanayake, E., Escobedo, A. K., You, D. G., Castro, C. M., Im, H., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101198 · Cited by 213
Early detection of lung cancer biomarkers through biosensor technology: A review
Roointan, A., Ahmad Mir, T., Ibrahim Wani, S., Mati-ur-Rehman, Hussain, K. K., Ahmed, B., Abrahim, S., Savardashtaki, A., Gandomani, G., Gandomani, M., et al. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.10.017 · Cited by 192
Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients
van Eijndhoven, M. A. J., Zijlstra, J. M., Groenewegen, N. J., Drees, E. E. E., van Niele, S., Baglio, S. R., Koppers-Lalic, D., van der Voorn, H., Libregts, S. F. W. M., Wauben, M. H. M., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89631 · Cited by 174
Circulating cell-free microRNAs as clinical cancer biomarkers
Armand-Labit, V., & Pradines, A. (2017) · Biomolecular Concepts · doi:10.1515/bmc-2017-0002 · Cited by 170
Permuth, J. B., Collaborative, T. F. P., Choi, J., Balarunathan, Y., Kim, J., Chen, D.-T., Chen, L., Orcutt, S., Doepker, M. P., Gage, K., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11768 · Cited by 127
“com/oncotarget data from other cancers which suggest that complementary biomarkers will increase specificity of standard-ofcare images [40, 41], our preliminary data infer that incorporating radiomic and miRNA expression data from images and blood obtained through standard of care has potential to accelerate discovery…”
BackgroundThe Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer
Cheng, Y. Y., Rath, E. M., Linton, A., Yuen, M. L., Takahashi, K., & Lee, K. (2020) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s186843 · Cited by 31
Metadata
- Authors
- Sozzi, G., Boeri, M., Rossi, M., Verri, C., Suatoni, P., Bravi, F., Roz, L., Conte, D., Grassi, M., Sverzellati, N., Marchiano, A., Negri, E., La Vecchia, C., & Pastorino, U.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-03-10
- Volume
- 32
- Issue
- 8
- Pages
- 768-773
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2103950317
- Cited by
- 436
- References
- 22
- FWCI
- 14.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.